Alnylam PharmD Fellowship Program

C H A L L E N G E A C C E P T E D

I N PA R T N E R S H I P W I T H

Program Guide and Application Information 2020-2022

A Message from Alnylam’s LeadershipWatching the Alnylam Fellowship Program expand since its inception five years ago has been truly remarkable. It has grown to involve multiple unique expertise areas, offering prospective fellows a diversity of experiences. For the biopharmaceutical industry, the fellowship allows us to develop a pipeline of top talent capable of tackling the complex challenges patients and their caregivers face every day. For Alnylam’s fellows, the opportunities here are limitless. The role of the fellow does not stop at the specific expertise area they are working in. The fellowship’s rotational component and Alnylam’s open-culture allows fellows to wear many different hats and explore interests in multiple expertise areas across the company.

Seeing our past fellows continue to serve the organization in various roles reflects the immense possibilities and gratifying work we do every day. At Alnylam, it is not only your degree or years of experience that dictate which roles and responsibilities you are able to take on. Rather, your skills, dedication, and commitment to patients are what allow you to thrive in this culture. My own professional trajectory is an example of this; I recently transitioned from a job I loved, serving as the Vice President of Medical Affairs, to becoming the General Manager of a late-stage pipeline program for a pediatric rare disease. As Alnylam evolves to becoming a global research, clinical development, and commercial company, I have no doubt that future fellows in the Alnylam Fellowship Program will continue to have unique, immersive, and unbounded experiences throughout their tenure.

Pritesh Gandhi, PharmD General Manager, Lumasiran Founder of the Alnylam/Northeastern Fellowship Program

_

TABLE OF CONTENTS

About Alnylam

Company Overview __________________________________________________4 Science and RNAi Platform _____________________________________________5

The Alnylam Fellowship Program Fellowship Program Overview __________________________________________6

Current Fellowships Recruiting _______________________________________7-12

Regulatory Affairs ______________________________________________7

Global Medical Affairs ___________________________________________8

Value & Evidence Strategy (VESt/HEOR) _____________________________9

Global Medical Information ______________________________________10

Fellowship Alumni __________________________________________________13

Northeastern University Northeastern Fellowship ______________________________________________14

Fellow Network/Life in Boston _________________________________________15

Application Information Application Process _________________________________________________16

Clinical Development ___________________________________________11

US Commercial ________________________________________________12

Founded in 2002, Alnylam Pharmaceuticals established an unwavering commitment to harnessing the power of RNA interference (RNAi) for treating rare conditions for patients with high unmet medical needs. Alnylam has lead the translation of RNAi to an innovative class of approved and investigational medicines used to treat a wide range of diseases using its powerful, clinically validated approach. In the summer of 2018, Alnylam established a new class of medicines, pioneering the delivery of RNAi therapeutics to patients through the FDA and EMA approval of ONPATTRO® (patisiran). This is the first of multiple launches anticipated in the “Alnylam 2020” guidance for the advancement and commercialization of RNAi therapeutics. The passionate and dedicated employees at Alnylam look forward to delivering its medicines to patients who need them around the world.

4

>1kEmployees

16Countries

2Approved Product*

>35Clinical Studies

to Date

>5yrsLongest Duration

of Exposure

COMPANY TRAJECTORY SNAPSHOT

10Programs

Currently in Clinical Development

Updated as of March 2020* 2 approved in the U.S. and in the EU, 1 of which is approved in Canada, Switzerland, Brazil and Japan

“ RNAi has been heralded as a major scientific breakthrough that happens once every decade or so.”

Phillip Sharp, Ph.D. Noble Laureate & Founder of Alnylam

Alnylam PharmaceuticalsCompany Overview

To those who say impossible, impractical, unrealistic,” we say:

CHALLENGE ACCEPTEDWe are relentless in our pursuit of new treatments. Because patients shouldn’t have to wait for hope.

WE HAVE BEEN NAMED A TOP PLACE TO WORK 5X IN A ROW

Return to TOC

20182015 2016 2017 2019

Return to TOC

RNAi was first discovered in the purple petunia flower and later translated into worms by biologists Andrew Fire and Craig Mello, marking a major scientific breakthrough while establishing a new frontier in drug development. Alnylam’s mission is to build a top-tier biopharmaceutical company founded on RNAi. Rather than treating symptoms, Alnylam’s approved and pipeline of investigational therapies work upstream of today’s medicines by silencing the messenger RNA (mRNA) that is transcribed into disease-causing or disease-contributing proteins. Through RNAi, patients are treated in a fundamentally new way.

Alnylam’s Science and RNAi Platform

FROM POSSIBILITIES TO PATIENTS

5

ALNYLAM CLINICAL DEVELOPMENT PIPELINE

ABOUT RNAi

1 POC, proof of concept – defined as having demonstrated target gene knockdown and/or additional evidence of activity in clinical studies2 Includes marketing application submissions3 Approved in the U.S. and Canada for the polyneuropathy of hATTR amyloidosis in adults, in the EU, Switzerland and Brazil for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy, and in Japan for the

treatment of transthyretin (TTR) type familial amyloidosis with polyneuropathy4 Approved in the U.S. for the treatment of adults with acute hepatic porphyria, and in the EU for the treatment of acute hepatic porphyria (AHP) in adults and adolescents over 12 years old5 Cemdisiran is currently in Phase 2 development and pozelimab is currently in Phase 1 development; Alnylam and Regeneron are evaluating potential combinations of these two investigational therapeuticsAs of March 2020

Focused in 4 Strategic Therapeutic Areas (STArs):

HUMAN POC1

BREAKTHROUGH DESIGNATION

EARLY STAGE(IND or CTA

Filed-Phase 2)

LATE STAGE (Phase 2- Phase 4)

REGISTRATION/ COMMERCIAL2

COMMERCIAL RIGHTS

ONPATTRO® (patisiran)3

Hereditary ATTR Amyloidosis

Global

GIVLAARI®️ (givosiran)4

Acute Hepatic Porphyria

Global

LumasiranPrimary Hyperoxaluria Type 1

Global

Inclisiran HypercholesterolemiaMilestones & up to

20% royalties

PatisiranATTR Amyloidosis Label Expansion

Global

FitusiranHemophilia and Rare Bleeding Disorders

15-30% royalties

Vutrisiran ATTR Amyloidosis Global

CemdisiranComplement-Mediated Diseases

50-50

Cemdisiran/ Pozelimab Combo5

Complement-Mediated Diseases

Milestone/Royalty

ALN-AAT02 Alpha-1 Liver Disease Global

ALN-HBV02(VIR-2218)

Hepatitis B Virus Infection

50-50 option rights post-Phase 2

ALN-AGT Hypertension Global

Genetic Medicines Cardio-Metabolic Diseases Hepatic Infectious Diseases CNS/Ocular Diseases

NEW CLASS OF MEDICINES

Return to TOC

In 2015, Alnylam Pharmaceuticals partnered with Northeastern University to offer a unique fellowship opportunity in the heart of Boston. The program set out to equip postdoctoral PharmDs with the skills necessary to develop the advanced medicines of the future, like RNAi. The goal was and remains the same: to cultivate the future leaders of biotechnology and allow fellows to pioneer new therapies for patients. Alnylam fellows are grounded in their core expertise area but utilize the fellowship’s flexibility to branch out and discover other opportunities throughout the organization with personalized rotational experiences. Part of the backbone of the fellowship program is the Northeastern University teaching opportunities which allow fellows to share their knowledge in an educational setting.

1. Ability to work in multiple therapeutic areas across pre-commercial, launch, and post-approval activities2. Vested interest and individualized mentoring from leading professionals in their field 3. Opportunities to engage in immersive, personalized rotations inside and out of one’s expertise area4. Ability to conduct academic research aligned with your interests under the mentorship of engaged

Northeastern faculty members5. Located in the heart of the world’s biotech hub, Cambridge, MA

Heather Sun, PharmDAlnylam Fellowship Program Director & Director, Medical Information

WHAT SETS THE ALNYLAM/NORTHEASTERN FELLOWSHIP APART?

Fellowship ProgramOverview

6 Return to TOC

Michael Gonyeau, PharmDNortheastern Fellowship Program Preceptor & Clinical Professor

Mark Douglass, PharmD, RPhNortheastern Fellowship Program Director & Associate Clinical Professor

Amy Monpara, PharmDAlnylam Fellowship Advisor & Medical Science Liaison

ACTIVELY RECRUITING: 1 FELLOW

Regulatory Affairs at Alnylam is a group with diverse scientific, technical, and clinical expertise. The team is responsible for creating and implementing innovative global strategies for expedited drug development and approval of Alnylam’s products. All stages of drug development are dependent on effective regulatory support and management, including the generation and filing of investigational new drug applications, clinical trial applications, and marketing applications, continuing throughout Alnylam’s product life-cycle. Unique experiences in the rare disease space include orphan drug applications, breakthrough therapy, and PRIME designation requests, and other novel regulatory pathways and approaches.

How is the Alnylam fellowship unique from your perspective? “Alnylam offers unparalleled opportunities and invaluable hands-on experiences! Within the

first month of joining, I have had the chance to collaborate and take ownership of several projects. There is always something new to learn and exciting to celebrate.”

Farida Azizova-Such, PharmD, RPh 1st Year Regulatory Affairs Fellow

What did you learn in your first year on the job? “In one year at Alnylam, I have gained more experience and knowledge than I ever could have

predicted. In this last year, I have had opportunities within regulatory that some will not experience for their whole careers. Even outside of my expertise area, I have development skills in management, organization, and communication that will translate to any path my career takes me.”

Caitlin Skenyon, PharmD, RPh 2nd Year Regulatory Affairs Fellow

Regulatory AffairsGlobal Regulatory Strategy

What characteristics do you believe define an Alnylam fellow?“One is ‘insatiable curiosity’. This characteristic emanates throughout Alnylam and has helped

the company make many scientific breakthroughs for patients. An Alnylam fellow should be insatiably curious about drug development, innovative science, and how all of this comes together in our submissions and interactions with Health Agencies. Another is being ‘team-oriented’. One of our core values is Commitment to People, including the diverse set of team members we work with daily from across different expertise areas. Drug development is a highly collaborative endeavor, and an Alnylam fellow will need to engage globally. This will provide skills and experiences to help in any career path they choose.”

Andrew Slugg, MS, MBA Regulatory Affairs Preceptor & Senior Vice President of Regulatory Affairs

ROLES AND RESPONSIBILITIES

• Working cross-functionally to support successful global regulatory submissions and filings • Supporting, preparing and submitting international marketing authorization applications (e.g., MAAs, NDAs)• Supporting the development and maintenance of regional labeling across programs• Coordination and management activities with internal team and external consultants• Regulatory annual report generation, management, and submission • Critical analysis and presentation of regulatory intelligence and industry surveillance

ROTATIONAL EXPERIENCES• International Regulatory

Affairs Strategy

• Advertising and Promotional Materials

• Global Labeling Strategy

• Chemistry, Manufacturing, and Controls

Return to TOC 7Return to TOC

The core responsibility of Medical Affairs at Alnylam is to advance medicines for patients with rare diseases. Medical Affairs achieves this through stakeholder engagement, dissemination of data, enabling diagnosis, and improving the care of patients. Fellows can expect to support Medical Affairs strategy through cross-functional collaborations to advance RNAi therapeutics. This position is ideal for determined and adaptable individuals seeking unique experiences within Global Medical Affairs.

Global Medical Affairs

ROLES AND RESPONSIBILITIES

• Creation of medical congress materials, including abstracts, presentations, and scientific symposia development• Engagement of key opinion leaders and patient advocacy groups • Coordination and execution of advisory boards • Execution of scientific communication strategy from development to commercialization• Collaboration with Commercial, Regulatory, and Clinical expertise areas• Additional experiences tailored to your career goals

ACTIVELY RECRUITING: 1 FELLOW

What excites you about Alnylam’s pipeline? “Not only do I get to learn from and work with a new therapeutic class of medications, but

the depth of Alnylam’s RNAi platform technology also provides me with opportunities to interact with products in different phases of the regulatory approval process. Understanding the intricate role Medical Affairs plays in these different instances is essential to growing my foundational knowledge that will set me up for a successful career.”

Katie Alfond, PharmD 1st Year Medical Affairs Fellow

Why did you choose Alnylam? “Alnylam creates opportunities to learn and collaborate with individuals beyond the traditional

fellowship experience. With Alnylam’s pipeline rapidly expanding in new disease states, I am fortunate enough to lay the foundational groundwork that gives patients with rare diseases hope in a new class of medicines.”

Jit Sheth, PharmD, RPh 2nd Year Medical Affairs Fellow

ROTATIONAL EXPERIENCES• Medical Communications

and Publications

• Field Medical (e.g. Medical Science Liaison)

• Patient Advocacy

• Value & Evidence Strategy/HEOR

• Medical Operations

8 Return to TOC

What is most rewarding about the fellowship and your role as a preceptor? “At Alnylam, fellows are not just an extension of our team; they are an integral part of our

team. Fellows will have the unique opportunity to explore different career paths in depth to determine what they want to pursue following this two-year fellowship. While no two fellowship experiences are alike, I am here to guide the fellow in navigating opportunities to ensure they are on a path to success.”

Ilia Antonino, PharmD Medical Affairs Preceptor & Director, Medical Communications and Publications

ACTIVELY RECRUITING: 1 FELLOW

The purpose of the Value and Evidence Strategy team at Alnylam is to lead evidence generation and value demonstration activities through cross-functional collaboration with Clinical Development, Market Access, Market Insights, Field Medical, and other expertise areas. VESt’s goal is to ensure excellence in evidence generation to allow Alnylam’s innovative medicines to reach patients and healthcare systems. The fellow will develop a thorough understanding of and hands on experience in health economics and outcomes research methodologies through various research initiatives and optional Master of Science coursework. The experience gained throughout this fellowship will allow the VESt fellow to scientifically evaluate a therapeutic’s clinical, humanistic, and economic impact.

Value and Evidence Strategy (VESt)Health Economics & Outcomes Research (HEOR)

ROLES AND RESPONSIBILITIES

• Conducting evidence gap analysis and data generation strategy to communicate the value of Alnylam’s products • Contributing to prospective and retrospective observational studies, cost-effectiveness analyses, comparative

effectiveness research, chart review studies, claims analyses, patient-reported outcomes research, and other studies with potential for publication

• Conducting burden of illness studies, epidemiologic research, and pharmacoeconomic analyses, as well as developing evidence dossiers for use by key healthcare decision makers

• Collaboration with peers/KOLs to obtain clinical input into evidence generation activities• Leading a Medical Affairs product sub-team and participating in cross-functional working groups

How is the Alnylam fellowship unique from your perspective? “There was not a better place to launch my career than here at Alnylam. It is an exciting and

innovative company located in the heart of Kendall Square, filled with pioneers committed to changing the lives of patients. Fellows are immersed into this high-energy environment as valued members of the team and work collaboratively to achieve ambitious goals.”

Jessica Baldwin, PharmD 1st Year Value and Evidence Strategy Fellow

What makes Alnylam stand out to you? “Passion. Every employee works tirelessly to provide access to potentially life-saving treatments

for the rare disease community. I feel extremely blessed to wake up every day knowing my work has the potential to change lives in more ways than I can imagine.”

Stephen Meninger, PharmD 2nd Year Value and Evidence Strategy Fellow

What are the learning opportunities in the VESt fellowship?“VESt fellows will take away far more than technical HEOR skills from this fellowship. Above all,

my objective is to mentor the fellow to think critically to solve problems to meet patient needs. This skill will be crucial to one’s success in any future role.”

Sonalee Agarwal, BPharm, PhD Value and Evidence Strategy Preceptor & Senior Director, Value and Evidence Strategy

ROTATIONAL EXPERIENCES• Market Access

• Commercial

• Field Medical/Payer Field Medical

• Patient Advocacy

Return to TOC 9Return to TOC

The Global Medical Information team serves to provide healthcare professionals, patients, and caregivers with balanced, accurate, and current medical information about Alnylam’s products. Medical Information engages cross functionally with other expertise areas such as Pharmacovigilance/Safety, Quality, Legal, Regulatory Affairs, Commercial, Clinical Operations, Clinical Development, and Information Technology, to ensure the safe, effective, and appropriate use of our therapies. Fellows in this program will partake in the development and launch of Medical Information services across the globe supporting multiple products. Furthermore, fellows sharpen their ability to read, interpret, and develop medical content accurately and fairly. While helping build the global medical information infrastructure to support Alnylam’s robust pipeline, the fellow will learn key project management skills as well.

Global Medical Information

ROLES AND RESPONSIBILITIES

• Global management of requests for medical information • Medical Information content development, including standard response letters, custom response letters, and FAQs• Adverse event and product quality complaint reporting• Data analytics and insights collection and reporting• Global product launch preparation and execution pertaining to medical information activities• Supporting of medical congress and information booth

ACTIVELY RECRUITING: 1 FELLOW

What inspires you about Alnylam? “Every single person at Alnylam works relentlessly to educate the community about the rare diseases

we aim to treat and advocate for patients who otherwise have few or no treatment options. Their tremendous effort does not go unnoticed, and it inspires me every day.”

May Le, PharmD 1st Year Global Medical Information Fellow

What are some of your goals and how does working at Alnylam support them? “An important professional goal of mine is to explore different expertise areas within the

biopharmaceutical industry to get a broad understanding of the work that goes behind bringing innovative medicines to patients. I knew by joining the Alnylam Fellowship Program that I would have access to opportunities in expertise areas across many of my interests. It’s exciting to know that I am the primary driver of my fellowship, making it an immersive and personalized experience.”

Ralph Reyes, PharmD, RPh 2nd Year Global Medical Information Fellow

ROTATIONAL EXPERIENCES• Medical Communications

and Publications

• Field Medical (e.g. Medical Science Liaisons)

• Commercial

• Pharmacovigilance and Safety

• Regulatory Affairs

10 Return to TOC

Why should a fellowship candidate consider the medical information fellowship at Alnylam?“The Alnylam Fellowship Program truly provides unique, hands-on experiences. The Global Medical

Information Fellow will have the opportunity to understand and become proficient in medical information operations on a global scale, while developing valuable skills that will contribute to future success in the biotech and pharmaceutical industry.”

Heather Sun, PharmD Global Medical Information Preceptor & Director, Medical Information

Return to TOC 11Return to TOC

ROLES AND RESPONSIBILITIES

• Operational, technical, and scientific aspects of generating clinical development plans and clinical trial execution from startup through closeout, including management of contract research organizations (CROs) and vendors

• Development of key study documents, including protocol concepts and protocols (Phase I-III, natural history), data capture tools such as case report forms, procedure manuals, study operation plans, informed consent forms, clinical study reports, and IND/NDA submission documents

• Engagement in ongoing medical data review, analysis, and reporting of clinical information in materials for sites, investigators, and other stakeholders. Planning and execution of investigator meetings and congresses to provide key messages about clinical trial data and study execution

• Participate in the development of effective working relationships with key investigators to optimize scientific quality/innovation of clinical study design, execution, reporting, and publication

• Process evaluation to ensure that all studies are conducted with the highest level of ethical and safety standards and in compliance with ICH/GCP guidelines and all applicable regulatory policies

ROTATIONAL EXPERIENCES• Regulatory Affairs

• Patient Recruitment & Retention

• Clinical Oversight and Systems

• Data Science & Statistics

• Pharmacovigilance/Patient Safety

• Pharmacokinetics/Pharmacodynamics

Clinical Development is the cornerstone of data generation in delivering novel medicines to patients. The Clinical Development fellowship at Alnylam will engage the fellow in work that is a fusion of scientific knowledge and operations of trial management to support clinical trial excellence. The fellow will start the fellowship in Clinical Operations, then rotate through Clinical Research, and have the option to select other expertise areas depending on the interests of the fellow. The intent of this program is to train fellows in comprehensive clinical development activities to build a foundation for roles as a clinical drug developer.

Clinical DevelopmentACTIVELY RECRUITING: 1 FELLOW

What does Sense of Urgency mean to you and how do you live it at work? “At Alnylam, the core value of Sense of Urgency means you will be a valued team member from day

one. We are racing to save and improve lives for patients with debilitating conditions. We recognize the critical imperative to find and enroll every patient who could benefit from our therapies. We live a Sense of Urgency every day by designing smart and efficient protocols, finding creative solutions to clinical trial challenges around the globe, and creating cutting-edge medicines that are highly effective, easily deliverable, and broadly indicated for maximum patient benefit in the widest patient population.”

Joshua A. Emerson, PharmD, RPh 1st Year Clinical Development Fellow

Why is now the right time for a fellow to join Alnylam as the Clinical Development fellow? “It is an incredible time in Alnylam Clinical Development with the approval of ONPATTRO® (patisiran) by the

FDA, EMA, and PMDA and multiple products in late stage development. You will join a fast-paced team who is integral in implementing global clinical trials using our small interfering RNA technology and delivering it to patients with few or no therapeutic options. Your fellowship will allow experiences contributing to the first studies in uncharacterized diseases to global pivotal efficacy trials for registration. The Clinical Development Fellowship will uniquely provide a Fellow multi-faceted vision and vertical access on what it truly takes to bring a novel therapy from first-in-man through to regulatory approval at this innovative biopharmaceutical company. Are you ready to roll up your sleeves and dive in with us at Alnylam?”

Raina Gay Leahy, PhD Clinical Development Fellowship Preceptor and Senior Manager, Clinical Operations

12 Return to TOC

In the summer of 2018, you helped launch ONPATTRO® (patisiran), the first FDA-approved RNAi therapeutic. What was this experience like?

“Being a part of the US launch team for ONPATTRO® (patisiran) has been the highlight of my career. Not only did we bring the first RNAi therapeutic to market, but patients with the polyneuropathy of hATTR amyloidosis now have an FDA-approved treatment option. As we neared launch, the energy and passion that is indigenous to Alnylam fueled our momentum. From the day of approval onward, it has been full steam ahead! We remain focused on increasing disease awareness and helping patients and their healthcare professionals learn about treatment with ONPATTRO® (patisiran). I look forward to continuing this work, as well as watching the company launch future RNAi therapeutics for patients with rare diseases.”

Christina Zhao, PharmD US Commercial Fellowship Preceptor & Associate Director, US Marketing, TTR

ROLES AND RESPONSIBILITIES

• Execution of personal promotion and targeted non-personal promotion tactics• Creation of product value messaging and disease awareness materials to support field personnel• Development of brand plan and brand positioning• Cross-functional collaboration with Patient Services, Commercial Analytics, and US field teams to support

launch activities• Commercial activities at key conferences, including booth development, product theaters, and sponsorships• Assessment of commercial opportunity and strategic fit of early pipeline assets including market sizing,

competitive landscape scanning, target product concept development, and revenue forecasts• Research lead to support pricing and reimbursement, forecasting, early-stage market planning, customer and

patient segmentation

ROTATIONAL EXPERIENCES• US Marketing

• Commercial Operations

• Market Insights

• Market Access

• New Product Planning

• Launch Excellence

The US Commercial team is responsible for defining and executing the US commercial strategy of Alnylam’s pipeline of RNAi therapeutics. Commercial achieves this through cross-functional collaboration with Medical Affairs, Regulatory Affairs, Clinical Development, and others. The US Commercial fellow will engage in the execution of strategic brand plans and key marketing initiatives, launch of new RNAi therapeutics, and the generation of commercial insights. This fellowship is for individuals who are entrepreneurial, biased for action, and enjoy working in a dynamic business environment. The fellow will gain key experiences and skills in communication, commercial execution, marketing and strategic planning.

US Commercial ACTIVELY RECRUITING: 1 FELLOW

How have you been able to apply your PharmD training to a commercial role within the industry?

“I quickly learned that to be a strong marketer within the biopharmaceutical industry, it’s imperative for me to develop a deep understanding of our product’s clinical trial design, study findings, and the disease state we are hoping to treat. My pharmacy training has prepared me to understand and dissect technical scientific information to formulate strategies that increase disease awareness to health care providers and patients. In the rare disease space, patients are often misdiagnosed, and it is our job to help providers accurately diagnose the disease so that the patients are able to receive optimal treatment”

David Iong, PharmD 1st Year US Commercial fellow

Return to TOC 13Return to TOC

Fellowship Alumni

Alex Wei, PharmD2015-2017 Medical Affairs FellowCurrent Role: Medical Director at Before Brands

The Alnylam Fellowship Program is proud to be able to watch our fellowship alumni continue their professional development in key roles within the company. The experiences and skills they gained during their fellowship tenure have become a launching pad for continued success and learning.

Dayna LeSueur, PharmD2016-2018 Regulatory Affairs Fellow

Current Role: Clinical Research Scientist

Anastasia McManus, PharmD2016-2018 Medical Affairs FellowCurrent Role: Senior Manager, Medical Communications

Ruthvik Malladi, PharmD2017-2019 Medical Affairs Fellow

Current Role: Manager, Medical Affairs

Madeline Merkel, PharmD 2017-2019 Value & Evidence Strategy Fellow (VESt)Current Role: Manager, Value and Evidence Strategy

Sarah Scott, PharmD2017-2019 Regulatory Affairs Fellow

Current Role: Senior Regulatory Specialist

Launch your post-graduate career with the Alnylam

Fellowship Program

NUfellowship.com

Northeastern University is a global, experiential, research university built on a tradition of engagement with the world, creating a distinctive approach to education and research. At Northeastern, we encourage our students to become engaged, confident, and resourceful global citizens who realize their knowledge and actions have a far-reaching impact. Students ignite their passion for learning and are exposed to the endless possibilities around them through transformative experiential education.

The Northeastern University Fellowship Program provides a dynamic academic environment offering fellows the opportunity for a wide breadth of experiences:

• Develop teaching skills through participation in our Teaching and Learning Seminar series

• Facilitate small and large group didactic education in partnership with a faculty mentor

• Utilize a layered learning model in experiential education by co-precepting students on pharmacy practice experiences including Northeastern’s unique co-op program

• Create, present, and publish scholarly research through collaborative industry and university relationships

• Engage with faculty who participate in various interdisciplinary graduate programs including biotechnology, nanomedicine, immunology, health informatics, and drug discovery

• Network with local residents and other Northeastern fellows via professional development programs, teaching seminars, and participation on fellowship committees

Andrew Orr-SkirvinDepartment Chair, Associate Clinical Professor & Fellowship Program Director

Debra Copeland Associate Clinical Professor & Fellowship Program Preceptor

Michael GonyeauClinical Professor & Fellowship Program Preceptor

Mark DouglassAssociate Clinical Professor & Fellowship Program Preceptor

Tayla RoseAssistant Clinical Professor & Fellowship Program Preceptor

Elizabeth MachartFellowship Program Administrator

CURRENT PARTNERS OF THE NORTHEASTERN UNIVERSITY FELLOWSHIP PROGRAM

Through these exciting partnerships, Northeastern fellows collaborate and learn from each other, further positioning them to be successful in both academic and industry settings. Fellows are empowered to shape their experience, as well as the future of the program, through leadership on the Professional Development & Networking and Recruitment committees.

Life in BostonNortheastern University is in the heart of Boston, steps away from the famous Fenway Park and downtown Boston. Surrounded by top tier academic and research institutions, the area is home to pioneers of innovation who are committed to intellectual curiosity and scientific advancement. The greater Boston area is a cultural hub, offering world-class attractions and rich history.

C H A L L E N G E A C C E P T E D

NUfellowship.com

QUESTIONS?

For more information and to apply: Visit: NUfellowship.com Email: PharmDFellowships@northeastern.edu

Address your cover letter and three letters of recommendation to: J. Andrew Orr-Skirvin, Pharm.D., BCOP Associate Department Chair, Department of Pharmacy & Health System Sciences Pharmaceutical Industry Fellowship Program Director Bouvé College of Health Sciences 360 Huntington Ave 140 The Fenway, R218 Boston, MA 02115

Email letters of recommendation to PharmDFellowships@northeastern.edu

Fellows will be selected on a nationally competitive basis. All candidates must have a Doctor of Pharmacy degree from an ACPE-accredited college of pharmacy by June 30, 2020. Candidates are encouraged to apply through the Northeastern website by the priority application deadline of December 1, 2019. Please see the graphic below for more information on the application process.

Application ProcessLaunch your post-graduate career. Apply now!

Apply at NUfellowship.com